There is a conversation that happens in almost every healthcare company. Usually in a legal or compliance review. Usually early. And it almost always ends the same way.
"We can't do patient marketing. Too much risk."
The brief is shelved. The budget goes elsewhere. The team moves on to the next campaign. And a quiet assumption hardens into policy: patient marketing is something other companies do, in territories with looser regulation, with larger budgets and more specialist resource. Not us.
The problem is that the assumption is almost always wrong.
What Most Companies Actually Do
Companies don't do nothing with patients. They invest significantly in patient-facing activity. They run adherence support programmes. They fund disease awareness platforms. They produce patient education content. They sponsor patient advocacy groups. Some of them sponsor clinical nurse specialists whose job is, in part, to help patients understand and stay on therapy.
This activity is real, it is valuable, and it is often genuinely well-funded. It sits, almost universally, in medical affairs.
And because medical affairs is running it, because it is governed by medical review, because it lives under the PV reporting structure, the commercial team counts it as their patient strategy. "We're already doing patient marketing," they say. "It's just handled by a different part of the business."
That framing is the problem. What they are describing is patient engagement. Not patient marketing. And conflating the two means the commercial growth opportunity from the patient pathway remains entirely untouched.
Why the Confusion Runs Deep
Patient engagement and patient marketing use the same words in their names. They both involve patients. They both produce patient-facing content. In many organisations, the same agency briefs both workstreams. You can see why the distinction gets blurry.
But the commercial outcomes are different in every meaningful way.
Patient engagement is about existing patients. It is about keeping someone on therapy once they are already diagnosed and prescribed. Adherence. Persistence. Understanding. Confidence in their treatment. The commercial benefit is retention: lower discontinuation rates, longer therapy durations, better outcomes. These are real returns. They are measured in adherence metrics.
Patient marketing is about new patients. It is about getting the right person in front of the right clinician in the first place. It is about increasing diagnosis rates, reducing time-to-treatment, expanding the pool of patients who are even having the relevant conversation with a relevant specialist. The commercial benefit is acquisition: more patients entering the pathway, more prescriptions initiated, more procedures performed. These are measured in acquisition metrics.
Most healthcare companies are measuring the former and assuming it tells them something about the latter.
It doesn't.
I've had this conversation with commercial teams across enough healthcare sectors now to have stopped being surprised by it. The adherence numbers are good. The new patient volume is flat. Nobody connects the two. (Ask me how I know.)
What's Actually Happening
The compliance fear that grounded patient marketing in the first place is not imaginary. Patient marketing is regulated. Claims must be evidenced. Content must be approved through medical-legal-regulatory review. In some territories, direct-to-patient advertising for prescription products is either prohibited or tightly controlled. There is genuine complexity here.
But genuine complexity is not the same as prohibition.
What most companies hit is not a legal "no." What they hit is the absence of a process. There is no claims matrix. There is no established review pathway for patient-facing commercial content. There is no template for co-branded clinic content. There is no precedent internally for what approval looks like. When legal is asked "can we do this?" and there is no framework to hang the answer on, the safest answer is "not yet." Which over time becomes "we don't."
The distinction matters because the solution is different. You can't build your way out of a prohibition. But you can build your way through a process gap. They require different responses.
The other thing that is actually happening is structural misalignment between who owns the problem and who has the authority to solve it. Patient marketing is a commercial problem. It requires a commercial budget, a commercial brief, and commercial metrics. But in most organisations it has been handed, by default, to medical affairs, who are equipped to run engagement and education programmes, not acquisition campaigns. They are excellent at what they do. It is simply not patient marketing as a commercial discipline.
A Different Approach
The companies that have built effective patient marketing programmes share a starting point that is not where most people expect: they started with the legal conversation.
Not to ask permission. To understand the actual constraints.
There is a significant difference between "can we do patient marketing?" (which invites a risk-based no) and "what would we need to have in place to run a compliant patient-facing campaign?" The second question produces a process. The first produces a veto.
What that conversation usually reveals is: a claims matrix is needed. A review pathway for patient-facing content needs to be defined. A position on co-branded clinic content needs to be established. Depending on territory and product type, there may be additional constraints. But these are buildable. None of them, in my experience, amount to a permanent prohibition for the large majority of healthcare companies in the UK and European markets.
The second step is finding a clinic partner before finding a platform. Patient marketing is most compliant and most effective when it is co-branded with the clinic treating the patients. The clinic has the relationship with the patient population. The clinic has a genuine interest in attracting more patients with the relevant condition. The clinic's brand on the content makes it clinical information rather than commercial advertising, which changes both the regulatory risk profile and the patient response.
Starting with the clinic also forces the right kind of specificity. Which patient population? Which geography? Which point in the patient journey? These questions are much easier to answer from inside a real clinical relationship than from a marketing brief.
Then: search. Where are patients going when they search for the condition your product addresses? Are you there? Is the clinic? In most cases, neither. This is the first genuinely addressable surface. It is also, for most categories, less regulated than advertising because it is informational rather than promotional. The compliance bar is lower. The cost is manageable. The feedback loop is fast.
Then: a claims matrix. Before any advertising runs. Every piece of patient-facing commercial content needs a document mapping each claim to its evidence base. This is not a creative brief. It is a legal instrument. It takes a day to build properly. It saves months of redrafts and review cycles because it gives the approval process something to work with.
Then, and only then: paid advertising. Targeted. Geographically bounded. Audience-specific. With a clear clinic destination and a pre-built claims set.
The sequence matters. Companies that start with advertising and then try to reverse-engineer the compliance infrastructure consistently conclude that patient marketing doesn't work. It doesn't work because they've built it backwards.
What One Company Did Instead
A mid-sized diagnostics company in the women's health space had been avoiding patient marketing for three years. Two previous attempts had stalled in legal review. The assumption had settled: too complicated, not worth it.
What they tried first: a broad awareness campaign, direct to consumer, with disease-state content and a product claim embedded. It went to legal. It came back with eleven amends. It went back. It came back with six more. By the third cycle the campaign was eighteen months old and the team had moved on.
The shift: a new commercial director asked a different question. Not "can we run patient marketing?" but "what would a compliant version actually look like, and what would we need to build first?"
The legal conversation revealed: no claims matrix existed. No review pathway for patient-facing content existed. No co-branded clinic framework existed. These were the gaps, not a prohibition.
Six months of infrastructure building: claims matrix for six key disease-state claims, a review pathway definition, a co-branding agreement template developed with their three largest clinic partners.
Then: a search campaign co-branded with two London clinics, targeted at women searching for symptoms associated with the relevant condition, driving to a clinic landing page.
Within nine months: 340 incremental patient enquiries across the two clinics. Both clinics expanded the agreement. The commercial team had a process they could repeat.
The activity itself was not complicated. Getting to the starting line was. (Still working on making that starting line easier to find, if I'm honest.)
Where to Start
If this argument lands, the practical question is not whether to do patient marketing. It is where in this sequence you currently are.
The first conversation is with legal and compliance. Not a "can we?" but a "what do we need?" Run that conversation now. Map the gaps. A claims matrix and a review pathway are both achievable in weeks, not quarters.
The second step is finding one clinic that already knows it needs more patients in the relevant indication. Most clinics do. Most have never been approached by a healthcare company with a co-branded marketing proposal. The pitch is simple: they bring the clinical credibility and the patient relationship, you bring the marketing infrastructure and the budget. The incentive alignment is clean.
The third step is building search presence for the condition, not the product. Patient-facing search content that answers the questions patients are actually asking. Compliant. Informational. Clinic-linked. This is the lowest-risk, highest-signal starting point.
Do not start with advertising. Build the infrastructure first. Run one compliant pilot with one clinic. Measure acquisition metrics, not adherence metrics. Then iterate.
The Real Stakes
The companies that figure out patient marketing first build a moat that is genuinely difficult for competitors to cross.
When you are generating patients for a clinic, the clinic's incentive to recommend a competitor product or to switch supplier is mostly gone. You are not just selling to them. You are part of their patient acquisition infrastructure. That relationship is sticky in a way that a good rep and a competitive price simply are not.
The compliance complexity that keeps most companies out is, in this light, not a deterrent. It is the barrier to entry. Working through it is the point.
This is worth starting now. Not because it is easy. Because it compounds.
What next?